Breaking News

The institute expects to announce its strategic plan in October 2020 to commemorate the 30th anniversary of the launch of the Human Genome Project.

Using pathway and network analyses, researchers identified overlapping genes and biological processes behind smoking and schizophrenia, including new candidate genes.

WUSTL bioinformatics spinout PierianDx disclosed in an SEC filing that it has raised slightly more than $3 million of a $5 million offering.

OpGen recently launched the first Acuitas test, which is designed to detect the most common bacterial causes of complicated urinary tract infections.

The test runs on the BD Viper LT system and detects 14 high-risk types of human papilloma virus.

The Regeneron Genetics Center will sequence the full exomes of all DNA samples in the non-profit group's open-access biospecimen repository.

The firm plans to use net proceeds for corporate purposes, including capital expenditures and working capital.

Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.

Invitae reported $25.4 million in fourth quarter revenues compared to $9.2 million in Q4 2016, beating the consensus Wall Street estimate.

Researchers from Rockefeller University sifted through soil microbiomes for genes linked to the function of calcium-dependent antibiotics.

While the President's budget proposal would slash the NIH's budget by 27 percent, the White House is seeking additional funding to bring the agency's budget to its 2017 level.

The proteomics firm is swapping 4 million of its shares for a 10 percent interest in CPR with the goal of moving into clinical trials and related research.

The university is arguing that the judge had no basis to compel arbitration of what Cornell is claiming is a fraudulent settlement.

Irish rare disease research center FutureNeuro is partnering with software vendor Congenica to bring sequencing to the point of care for genetic epilepsies.

The financing will support the company as it works to expand its diagnostic products for non-invasive early detection and monitoring of cancers.

Last week, GenomeWeb's readers were most interested in a study that found some de novo mutations that occur in people with autism may impact motor skills.

During the quarter, the company reopened its CLIA lab in New Haven, Connecticut, following the company's merger with Transgenomic in June.

Overall, revenues were up 8 percent. In the diagnostics segment, molecular product sales were driven primarily by continued strength across Aptima women's health products.

The firm posted revenues of $530.5 million, with organic growth at 4 percent and acquisitions and currency effects adding 4 percent and 5 percent, respectively.

Revenue increases for the firm's for high-throughput genomics and mass cytometry products were offset by declines in single-cell genomics product sales.

DiscernDx, which is backed by Khosla Ventures, stepped in to purchase API's assets after lender Square 1 Bank asserted a lien on the company late last year.

The US ITC has ruled that Oxford Nanopore's products do not infringe on single-molecule sequencing-related patents held by PacBio. 


Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.